ISDA: 6LZG

Deposition Date 2020-02-19

Release Date 2020-03-18

Last Version Date 2024-11-06

Entry Detail

PDB ID:

6LZG

Keywords:

VIRAL PROTEIN

Title:

Structure of novel coronavirus spike receptor-binding domain complexed with its receptor ACE2

Biological Source:

Source Organism(s):

Homo sapiens (Taxon ID: 9606)
Severe acute respiratory syndrome coronavirus 2 (Taxon ID: 2697049)

Expression System(s):

Insect cell expression vector ptie1

Method Details:

Experimental Method:

X-RAY DIFFRACTION

Resolution:

2.50 Å

R-Value Free:

0.21

R-Value Work:

0.18

R-Value Observed:

0.18

Space Group:

P 41 21 2

Download Validation Report

Macromolecular Entities

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Angiotensin-converting enzyme 2
Gene (Uniprot):ACE2
Chain IDs:A
Chain Length:596
Number of Molecules:1
Biological Source:Homo sapiens

UniProt ID:Q9BYF1 Pfam ID:PF01401 EC:3.4.15.1

Structures with similar UniProt ID

Protein Blast

Polymer Type:polypeptide(L)
Molecule:Spike protein S1
Gene (Uniprot):S
Chain IDs:B
Chain Length:209
Number of Molecules:1
Biological Source:Severe acute respiratory syndrome coronavirus 2

UniProt ID:P0DTC2 Pfam ID:PF09408

Ligand Molecules

NAG

Primary Citation

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2.

Wang, Q, Zhang, Y, Wu, L, Niu, S, Song, C, Zhang, Z, Lu, G, Qiao, C, Hu, Y, Yuen, K.Y, Wang, Q, Zhou, H, Yan, J, Qi, J.Show

Cell 181 894 904.e9 (2020)

PMID: 32275855 DOI: 10.1016/j.cell.2020.03.045

Abstact

The recent emergence of a novel coronavirus (SARS-CoV-2) in China has caused significant public health concerns. Recently, ACE2 was reported as an entry receptor for SARS-CoV-2. In this study, we present the crystal structure of the C-terminal domain of SARS-CoV-2 (SARS-CoV-2-CTD) spike (S) protein in complex with human ACE2 (hACE2), which reveals a hACE2-binding mode similar overall to that observed for SARS-CoV. However, atomic details at the binding interface demonstrate that key residue substitutions in SARS-CoV-2-CTD slightly strengthen the interaction and lead to higher affinity for receptor binding than SARS-RBD. Additionally, a panel of murine monoclonal antibodies (mAbs) and polyclonal antibodies (pAbs) against SARS-CoV-S1/receptor-binding domain (RBD) were unable to interact with the SARS-CoV-2 S protein, indicating notable differences in antigenicity between SARS-CoV and SARS-CoV-2. These findings shed light on the viral pathogenesis and provide important structural information regarding development of therapeutic countermeasures against the emerging virus.

Legend

Protein

Chemical

Disease

Primary Citation of related structures

Abstact

Feedback Form